Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs nVent Electric (NVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs nVent Electric — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while nVent Electric trades at $148.5 (market cap $24.72B). The key difference: nVent Electric is far larger — about 25.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and nVent Electric pays a 0.55% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and nVent Electric for 14 Days on average.
| MRVI | NVT | |
|---|---|---|
Market Cap | $977.37M | $24.72B |
Volume | 2,742,564 | 2,529,194 |
Sector | Health | Industrials |
52-Week High | $9.00 | $184.34 |
52-Week Low | $2.83 | $94.99 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $1.08B | $26.10B |
Dividend Yield | — | 0.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NVT trades at $161.47, down 0.8% with a bullish technical outlook and strong institutional support. The company demonstrates robust earnings momentum with three consecutive quarterly beats and a 61% YTD surge driven by AI data-center demand. Recent developments include the $1.75 billion acquisition of Maverick Power and a strategic collaboration with AMD on cooling solutions for AI infrastructure, positioning NVT for continued growth in the expanding data center market.
While NVT's premium valuation (P/E 44.85) and rising competition present risks, strong analyst consensus (85% buy rating) with a $203.86 price target suggests 26% upside potential. The company's expanding AI infrastructure portfolio and solid cash flow generation support long-term growth, though investors should monitor tariff impacts and valuation compression risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About nVent Electric
nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →
